David Sommerhalder MD

Oncology•San Antonio, TX

Clinical Investigator, Hematologist/Oncologist at NEXT Oncology

Join to View Full Profile

2829 Babcock RdSte 300San Antonio, TX 78229
Phone+1 210-580-9500
Fax+1 210-568-4397

Summary

Dr. David Sommerhalder is an oncologist in San Antonio, TX and is affiliated with multiple hospitals. He works as a phase 1 oncology investigator at NEXT Oncology in affiliation with Texas Oncology. He completed his residency and fellowship at LSU. He also speaks multiple languages, including Spanish. He is or has been principal investigator on over 50 trials.

Education & Training

Louisiana State University (Shreveport)Fellowship, Hematology and Medical Oncology, 2017 - 2020
Louisiana State University (Shreveport)Residency, Internal Medicine, 2014 - 2017
Ross UniversityMD, 2010 - 2013
Ross University School of MedicineClass of 2013

Certifications & Licensure

TX State Medical License 2020 - 2026
LA State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Chief Fellow, Hematology/Oncology LSUHSC Shreveport, 2019-2020
Chief Resident, Internal Medicine LSUHSC Shreveport, 2016-2017

Clinical Trials

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies Start of enrollment: 2021 May 06
Terminated
Phase 1
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Start of enrollment: 2023 Oct 24
RECRUITING
PHASE1, PHASE2
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors Start of enrollment: 2021 Apr 13
Recruiting
Phase 1
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Oct 31
RECRUITING
PHASE1, PHASE2
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Start of enrollment: 2019 Oct 25
Recruiting
Phase 1, Phase 2
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Feb 25
Recruiting
Phase 1
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2023 Oct 18
RECRUITING
PHASE1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors Start of enrollment: 2021 Mar 09
RECRUITING
PHASE1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors Start of enrollment: 2023 Oct 24
Recruiting
Phase 1, Phase 2
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Start of enrollment: 2022 May 31
RECRUITING
PHASE1
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors Start of enrollment: 2023 Nov 14
RECRUITING
PHASE1
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors Start of enrollment: 2024 Feb 06
RECRUITING
PHASE1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Start of enrollment: 2021 Oct 13
ACTIVE_NOT_RECRUITING
PHASE1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab Start of enrollment: 2021 Nov 01
RECRUITING
PHASE1
A Study of ASP2074 in Adults With Solid Tumors Start of enrollment: 2023 Feb 28
TERMINATED
PHASE1
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Start of enrollment: 2021 Oct 18
RECRUITING
PHASE1
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Start of enrollment: 2023 Jan 12
TERMINATED
PHASE1
Dose Escalation Trial of BNT152+153 in Patients With Cancer Start of enrollment: 2021 Jun 08
ACTIVE_NOT_RECRUITING
PHASE1
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors Start of enrollment: 2021 Aug 18
RECRUITING
PHASE1
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors Start of enrollment: 2023 Oct 09
RECRUITING
PHASE1
Safety and Tolerability of Intravenous Administration of ICVB-1042 Start of enrollment: 2023 Jun 01
TERMINATED
PHASE1
A Study of NDI 1150-101 in Patients With Solid Tumors Start of enrollment: 2021 Nov 05
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Nov 16
RECRUITING
PHASE1
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies Start of enrollment: 2023 Mar 03
Recruiting
Phase 1
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Start of enrollment: 2022 Sep 19
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2023 Feb 17
ACTIVE_NOT_RECRUITING
PHASE1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors Start of enrollment: 2024 Jan 05
RECRUITING
PHASE1
A Study of YL201 in Patients with Advanced Solid Tumors Start of enrollment: 2022 May 25
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Yuxiang Ma, Yunpeng Yang, Yan Huang, Wenfeng Fang, Jinhui Xue
Nature Medicine. 2025-03-13
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder
Cancer Research Communications. 2024-09-01
6 citations
Inhibition of lysine acetyltransferase KAT6 in ERHER2metastatic breast cancer: a phase 1 trial.
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Hamilton
Nature Medicine. 2024-08-01

Abstracts/Posters

The impact of obesity on the response rates of checkpoint Inhibitor (CPI) cancer immunotherapy
Philip A. Haddad, MD, MPH; David Sommerhalder, MD;, SITC, National Harbor, 11/8/2019
The impact of Metformin (M) on the response rates of checkpoint Inhibitors (CPI)
Philip A. Haddad, MD, MPH; David Sommerhalder, MD;, SITC Conference, National Harbor, 11/7/2019